drugset / Trial / NCT01257178
A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to evaluate the impact of hepatic dysfunction on the pharmacokinetics and safety of LY2624803 and its major metabolite, LSN2797276.
Timeline
- Start
- 2010-11
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2624803 | Small molecule | 6 mg | Oral |